Ergoteles LLC Nektar Therapeutics Transaction History

Ergoteles LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $19,875 - $38,625	37,500 New	37,500 $21,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $58,340 - $98,641	19,191 New	19,191 $61,000
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $256,284 - $498,825	-80,847 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $218,583 - $720,903	52,544 Added 185.65%	80,847 $436,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $568,585 - $966,543	-52,501 Reduced 64.97%	28,303 $382,000
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $219,994 - $317,114	-16,832 Reduced 17.24%	80,804 $1.45 Million
Q2 2021 Aug 12, 2021	BUY	$16.52 - $20.4 $1.16 Million - $1.43 Million	70,040 Added 253.8%	97,636 $1.68 Million
Q1 2021 May 12, 2021	SELL	$16.56 - $25.46 $1.32 Million - $2.04 Million	-80,004 Reduced 74.35%	27,596 $552,000
Q4 2020 Feb 11, 2021	BUY	$15.77 - $19.03 $1.7 Million - $2.05 Million	107,600 New	107,600 $1.83 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.